Ludwig Merker

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Simon Heller, John B. Buse, Miles Fisher et al. · The Lancet · 2012 · 401 citations

Type 1, Diabetes Management, Insulin Degludec +7

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Hans‐Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker et al. · Diabetes Care · 2014 · 383 citations · Full text

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes

Hans‐Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker et al. · Diabetes Care · 2013 · 368 citations · Full text

Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus

Christopher S. Kovács, Veeraswamy Seshiah, Ludwig Merker et al. · Clinical Therapeutics · 2015 · 109 citations

Diabetes Management, Medicine, Insulin Management +6

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN^® Basal–Bolus Type 1): 2‐year results of a randomized clinical trial

Bruce W. Bode, John B. Buse, Miles Fisher et al. · Diabetic Medicine · 2013 · 94 citations · Full text